A menopause review connects GSM care with sexual comfort while distinguishing desire concerns and ongoing STI prevention.
On October 19, 2026, Jorge Rojas published the Spanish-language review Salud sexual y menopausia: qué dice la evidencia on Sexualidad Basada en Evidencia. The review connects genitourinary syndrome of menopause with sexual comfort and desire while keeping sexually transmitted infection prevention in the discussion after fertility declines.
The symptom-focused care described in the review includes lubricants and vaginal moisturisers for milder symptoms. It also discusses low-dose vaginal oestrogen for symptoms that persist or are more severe. These approaches address physical concerns such as dryness and pain.
The review broadens that discussion rather than announcing a replacement standard of care. Its central distinction is that treating uncomfortable sex and addressing low desire are related tasks, but they are not interchangeable. It also separates pregnancy prevention from protection against sexually transmitted infections, or STIs.
That framing matters because a conversation focused only on vaginal symptoms leaves other questions unanswered. Has desire changed? Is pain contributing to avoidance? Do partners or sexual exposure make infection prevention relevant? The review brings these questions together without presenting one treatment as an answer to all of them.
One useful implication of the review is a clearer vocabulary for a healthcare conversation. Dryness describes a physical symptom. Pain describes another experience. Desire concerns interest in sexual activity. The review treats these as connected areas that deserve separate attention.
This makes room for more precise descriptions than a broad statement that sex has changed. A discussion can distinguish discomfort during sexual activity from reduced interest in it. It can also identify whether both are happening, without assuming that one fully explains the other.
The review’s account of pain and avoidance adds another layer. Where discomfort is contributing to reduced interest, that connection belongs in the assessment. Where sleep or mood is part of the picture, those concerns should not disappear simply because a physical symptom has been identified.
The editorial lesson is to preserve the distinction throughout care: improving comfort is a meaningful outcome in its own right. It does not have to stand in for a claim about desire. Readers looking for context on finding professional support for different sexual concerns can use that distinction to frame their questions.
The review’s treatment discussion starts with the nature and persistence of symptoms rather than a universal product recommendation. Lubricants and moisturisers appear within its discussion of milder concerns. Vaginal oestrogen appears within the discussion of more persistent or severe symptoms. Personal treatment decisions belong with a qualified healthcare professional.
A history of cancer receives particular attention in the review’s call for individual assessment. That is not a basis for a blanket instruction either to use or avoid a treatment. It is a reason for the clinical conversation to include medical history rather than relying on a general description of an option. Refemina’s coverage of how other health conditions shape menopause care provides related context.
The review also leaves room for pelvic-floor or sexological support when relevant factors are present. Its broader message is that physical symptom care need not carry the whole responsibility for sexual wellbeing. Different concerns may call for different forms of professional attention.
The review separates two questions that can otherwise become tangled: whether pregnancy prevention is needed and whether infection protection is relevant. Its discussion does not establish when contraception can stop. Instead, it makes the narrower point that reduced pregnancy risk does not mean STI risk has disappeared.
For prevention discussions, the review points towards partners and exposure. New or non-exclusive partnerships are examples it gives when discussing condoms. That framing keeps the conversation specific without treating menopause itself as either protection from infection or a reason for alarm.
Testing questions also belong in a professional sexual-health conversation shaped by exposure and circumstances. The practical value is not a universal testing timetable. It is keeping prevention visible alongside comfort and desire. A conversation about respectful and personalised sexual healthcare can accommodate all of those concerns without making assumptions about a woman’s relationships.
This publication is a review of existing evidence rather than a new treatment trial. The supplied research chiefly verifies the review itself, not independent confirmation of all its clinical claims. Its treatment summary provides no trial effect sizes or treatment-duration figures. These boundaries support using the article as a framework for informed discussion rather than as a new clinical protocol. Detailed screening decisions still need current local guidance and qualified care.
The review points clinical conversations towards a more precise approach: assess comfort and desire separately while keeping infection prevention visible as fertility declines.
Sexual wellbeing after menopause is poorly served when pain and desire are collapsed into one problem or infection prevention disappears from the discussion. Refemina places intimate comfort and sexual confidence within its wider coverage of hormonal transition, helping women understand credible evidence without turning every concern into a hormone or supplement opportunity.
Follow Refemina for research-led insights on menopause, strength, metabolism, nutrition, skin, intimacy and confidence through midlife. New articles turn complex topics into clear, useful context.
Keep learning about the changes that shape energy, strength, confidence and wellbeing through midlife.
Explore Resources